Neisseria gonorrhoeae-Induced Human Defensins 5 and 6 Increase HIV Infectivity: Role in Enhanced Transmission

Mary E. Klotman, Aprille Rapista, Natalia Teleshova, Amanda Micsenyi, Gary A. Jarvis, Wuyuan Lu, Edith Porter and Theresa L. Chang

J Immunol 2008; 180:6176-6185; doi: 10.4049/jimmunol.180.9.6176
http://www.jimmunol.org/content/180/9/6176

References
This article cites 80 articles, 36 of which you can access for free at:
http://www.jimmunol.org/content/180/9/6176.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Sexual contact is the most common route of HIV transmission. Women comprise nearly 50% of those infected worldwide and >70% in sub-Saharan Africa (1, 2). Prevention strategies using multiple approaches are urgently needed to reduce the probability of transmission. Epidemiological and clinical studies indicate that sexually transmitted infections (STIs) significantly increase the likelihood of HIV transmission (3–7), although the underlying mechanisms are not clear. STIs not only increase HIV shedding in HIV-infected adults, they also increase susceptibility to HIV infection in those who are HIV negative (3, 4, 8). The adjusted odds ratios for HIV acquisition range from 2.2 to 11.3 for individuals with ulcerative diseases, and from 3 to 4 for nonulcerative STIs (3, 8). Although the contribution of STIs to the sexual contact is among the most common modes of HIV transmission (1, 2). Epidemiological and clinical studies indicate that sexually transmitted infections (STIs) significantly increase the likelihood of HIV transmission (3–7), although the underlying mechanisms are not clear. STIs not only increase HIV shedding in HIV-infected adults, they also increase susceptibility to HIV infection in those who are HIV negative (3, 4, 8). The adjusted odds ratios for HIV acquisition range from 2.2 to 11.3 for individuals with ulcerative diseases, and from 3 to 4 for nonulcerative STIs (3, 8). Although the contribution of STIs to the increase in HIV transmission is multifaceted (reviewed in Refs. 3 and 4), understanding these mechanisms will contribute to the development of new strategies to reduce the spread of HIV. Gonorrhea, caused by the Gram-negative diplococcus Neisseria gonorrhoeae, remains a major global health problem; >60 million new cases are diagnosed worldwide each year (9). Men with gonorrhea frequently have acute urethritis, an inflammatory response resulting from gonococcal (GC) infection (10). In contrast, 50–80% of women with lower genital tract GC infection are asymptomatic (11, 12) and 45% of women with GC cervicitis will develop an ascending infection, a prerequisite for pelvic inflammatory disease (13, 14). Thus, individuals with asymptomatic GC infection are particularly at risk for acquiring HIV. GC can adhere to and penetrate mucosal epithelial cells, access submucosal sites, and interact with immune cells (15). GC infection of epithelial cells involves the phase-variable expression of several outer membrane components, including pili, opacity-associated (Opa) proteins, lactosyl lipooligosaccharide (LOS), and the PorB porin protein. Recently, LOS, which interacts with TLR4 (16), has been shown to induce the secretion of TNF-α, IL-1β, IL-6, and IL-8 in male primary urethral epithelial cells (17). These are the same cytokines that are prevalent in the urethral lumen in active GC infection. Studies of cytokine induction in response to GC infection in women have not been consistent (14); IL-1, IL-6, and IL-8 levels are not increased in genital tract secretions from women with GC cervicitis (18) but are elevated in GC-exposed human cervical and vaginal epithelial cell lines (19). In men with GC urethritis, HIV RNA is decreased in semen following treatment for GC (5). GC infection is reported to enhance HIV infection in vitro by activating the HIV long terminal repeat (LTR) in transformed T cells (20) or in vivo by increasing the number of endocervical CD4+ T lymphocytes in GC-infected women (21). Recently, GC infection has also been shown to enhance HIV infection in monocyte-derived dendritic cells by activating TLR2 (22).
Mammalian defensins are antimicrobial peptides important to innate host defense and are thought to play a role in mucosal immunity (23–26). Indeed, in humans, defensin levels in the mucosa are frequently elevated in response to mucosal infection (27–29), suggesting a potential role in modulating STIs, including HIV. Human neutrophil peptides (HNP)s 1–4 from neutrophils and human β-defensins (HBDs) 2 and 3 from epithelial cells exhibit anti-HIV-1 activity (30, 31), whereas HBD1 displays little anti-HIV activity (32, 33). Defensins with anti-HIV activity appear to inhibit HIV through multiple mechanisms; different defensins may have similar or distinct antiviral actions (30, 31). For example, HNP1 plays a dual role in anti-HIV innate immunity (34) by acting on HIV virions and target cells. It also blocks HIV infection of macrophages by up-regulation of CC chemokines (35). On the target cell, HNP1 interferes with HIV nuclear import and transcription after entry. At least one of the cellular effects associated with HIV inhibition by HNP1 is interference with protein kinase C signaling in primary CD4+ T cells (34). Similarly as HNPs, HBDs exhibit multiple anti-HIV functions (32, 33). Unlike HNP-1, HBDs only display the direct effect on a HIV virion under a low salt condition (10 mM phosphate buffer) (32). After viral entry, HBD2 inhibits the formation of early reverse-transcribed HIV products (32, 33). In addition, HBDs 2 and 3 down-regulate the HIV coreceptor CXCR4 in PBMCs in the absence of serum (32), and HBD3 competes with stromal-derived factor 1, the natural ligand for CXCR4 (36).

Human α-defensins HD5 and HD6 are constitutively expressed by intestinal Paneth cells, playing an important role in gut mucosal immunity (23–26). HD5 is also found in cervical lavage fluid as well as in the epithelium of the vagina and the ectocervix (37, 38). A recent report indicates that HD5 is induced in the male urethra during Chlamydia trachomatis and N. gonorrhoeae infection (29), further supporting a role for defensins in patients with STIs. Considering the clinically observed association of GC infection and increased HIV incidence and the up-regulation of HD5 in gonococcal urethritis, we investigated the role of defensins in STI-mediated HIV enhancement. Our study demonstrated, for the first time, that HD5 and HD6 actually enhanced HIV infection and therefore may contribute to GC-mediated HIV enhancement. These studies highlight the complexity of the interactions between an innate immune response and HIV transmission and may offer insights into novel approaches to prevent HIV infection by targeting HD5 and HD6.

Materials and Methods

HD5, HD6, and pro-HD5 peptides

HD5 and HD6 as well as linear unstructured forms of HD5 and HD6, [Abu]HDS and [Abu]HJHD6, in which the six cysteine residues were replaced by isosteric α-aminothiobutyric acid (Abu), were chemically synthesized and folded as described previously (39). The molecular mass of the peptides was verified by electrospray ionization mass spectrometry as described previously (39). Both synthetic HD5 and HD6 are correctly folded as indicated through structural analysis by x-ray crystallography (40). Recombinant HD5 propeptide (aa 20 to 94) was biosynthesized using the baculovirus/insect cell culture system as previously described (41).

Cell culture

PBMCs from normal healthy blood donors were isolated by Ficoll-Hypaque gradient centrifugation. CD4+ T cells were isolated from PBMCs by negative selection using a CD4+ T cell isolation kit from Miltenyi Biotec. The purity of cells is 98% based on flow cytometry analysis. CD4+ T cells were stimulated with PHA at 5 μg/ml and maintained in RPMI 1640 medium supplemented with 10% FBS and IL-2 at 25 U/ml for 3 days at 37°C before viral infection. HeLa-CD4-C4R5 cells were provided by D. Kabat (University of Oregon, Portland, OR) and maintained in DMEM containing 10% FBS. U87-CD4-C4R5 cells were obtained from D. Kabat (University of Oregon, Portland, OR) and maintained in DMEM containing 10% FBS.

Immunoblotting analysis

HD5 proteins were analyzed by immunoblotting as described previously (29) with modifications. Samples (300 μl) from conditioned medium without or with GC exposure were analyzed by immunoblotting with protein analysis. Whole cell extracts were prepared by lysis of cells in 20 mM HEPES.
FIGURE 1. HD5 and HD6 enhanced HIV infection. To examine the effect of defensins on HIV infection, serum-free pseudo-typed HIVJR-FL virus were incubated with HD5 or HD6 at various concentrations at 37°C for 1 h followed by infection of HeLa-CD4-CCR5 cells (A) or PHA-activated CD4+ T cells (B) for 2 h. Cells were washed and incubated in complete medium for 48 h before measuring luciferase activity. Difference between control (HIV-1 infected, no treatment) and samples with treatment of HD5 or HD6 at 10 µg/ml and above is significant as calculated by the two-tailed, paired Student’s t test; *, p < 0.05. Data are means ± SD of triplicate sample and represent four independent experiments. R.L.U., reflective light units.

RNA interference
Small interfering RNAs (siRNA) targeting HD5 or HD6 were introduced into human vaginal epithelial cells by transfection using HiPerFect transfection reagent (Qiagen) according to the manufacturer’s suggestions. All Stars negative control siRNA and siRNAs for HD5 or HD6 were purchased from Qiagen. The target sequences for HD5 and HD6 were 5’-AGCTTCTAGATAGAAACCAA-3’ and 5’-CAGAGGAAAAATATATCTACAA-3’, respectively. Using the Qiagen fast-forward transfection protocol, cells were seeded at 7 x 10^5 in a 6-well plate followed by transfection with various siRNAs at 10 nM. Transfection efficiency was 90% by FACS analysis using Alexa Fluor 488-labeled siRNA at 10 nM. Transfected cells were incubated overnight, washed with PBS, and cultured in fresh medium before GC exposure as described above. After exposure to GC for 48 h, cells were washed and specific bands were visualized using the ECL kit (Amersham Biosciences). Immunoblotting for HD6 could not be performed due to the lack of an Ab.

RT-PCR analysis of HD5 and HD6 gene expression
Total RNA was isolated using a Qiagen RNeasy total RNA mini kit with treatment by RNase-free DNase I. To synthesize first-strand cDNA, total RNA (200–500 ng), oligo d(T)₁₂ (Invitrogen) at 2.5 µg/ml, and 0.5 mM dNTPs were incubated at 65°C for 5 min and quick chilled on ice. Reverse transcription was performed at 42°C for 50 min using SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. Primers for RT-PCR with HD5 and HD6 were 5’-ACCTCAGGTTCTCAGGCAAGAC-3’ (HD5 forward) and 5’-GAACAAAGGTACACAGATGAAATGT-3’ (HD5 reverse) and 5’-GCTTTGGGCTCACAAGGCTTTC-3’ (HD6 forward) and 5’-GACACAGCAAGTCTCTACTTAGTGTCA-3’ (HD6 reverse) (46). Primers for GPDH were 5’-ACCAAGTCCATGACCAC3’ (forward) and 5’-TCCACACCCCTGTTGCTGTA-3’ (reverse). The PCR contained Qiagen Tag master mix, 200 nM each of primer sets, and 3 µl of reverse transcriptase reaction. After an initial incubation at 94°C for 3 min, 35 cycles of amplification were performed as follows: denaturation for 30 s at 94°C, annealing for 30 s at 55°C, and 30 s at 72°C, and a final extension cycle of 7 min at 72°C in a PerkinElmer 480 DNA thermal cycler. PCR products were separated by electrophoresis on a 2% agarose gel and analyzed with the FluoroChem 8800 imaging system (Alpha Innotech).

Results

HD5 and HD6 enhance HIV infection
We first determined whether HD5 and HD6 displayed any effect on HIV infection using a single-cycle infection assay. Serum-free HIV-1JR-FL-pseudotyped luciferase reporter virus was incubated with varying concentrations of HD5 or HD6 for 1 h at 37°C before exposure to PHA-activated primary CD4+ T cells or HeLa-CD4-CCR5 cells for 2 h at 37°C. After washing off unbound virus, infected cells were incubated for 48 h before measurement of luciferase activity. Both HD5 and HD6 promoted HIV infection (Fig. 1, A and B) in contrast to previous findings showing that HNPs and HBDs block HIV infection (reviewed in Refs. 30 and 31). HIV-1 replication was enhanced 41- and 67-fold in HeLa-CD4-CCR5 cells following treatment of virus with HD5 at 10 and 50 µg/ml, respectively. Similarly, HD5 at 10 and 50 µg/ml enhanced HIV-1 replication by 64- and 116-fold, respectively (Fig. 1A). HD5 and HD6 also significantly enhanced HIV infection observed in PHA-activated primary CD4+ T cells (15- or 78-fold with treatment of HD5 and HD6 at 10 and 50 µg/ml, respectively) and U87-CD4-CCR5 cells (Fig. 1B; data not shown for U87 cells). In addition, we found that HD5 and HD6 enhanced HIV infection in the presence of 10% FBS or human serum, albeit at lower levels (e.g., 5- to 20-fold, depending on the concentrations of defensins; data not shown).

HD5 and HD6 do not promote cell proliferation or inhibit HIV infection after viral entry
To determine whether the defensin-mediated HIV enhancement was due to a mitogenic effect on the cell, we measured the effect of HD5 or HD6 at concentrations from 50–500 ng/ml along with a mitogenic control, 100 ng/ml of PHA, for up to 48 h. Cell proliferation was measured using the CellTiter96 AQueous One Solution Cell Proliferation Assay kit (Promega), and the results were compared to a control of PHA treatment. No differences were observed in cell proliferation at any concentration (data not shown). HD5 or HD6 did not inhibit HIV infection in the presence of 10% FBS or human serum, albeit at lower levels (e.g., 5- to 20-fold, depending on the concentrations of defensins; data not shown).
of HD5 and HD6 on cell proliferation using an 3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay. PHA-activated PBMCs or HeLa-CD4-CCR5 cells were treated with HD5 and HD6 at varying concentrations for 24 h before measurement of cell proliferation. HD5 and HD6 at 50 μg/ml did not have a significant effect on cell proliferation (Fig. 2A and data not shown for HeLa-CD4-CCR5). In agreement with previous report demonstrating that HD5 is not cytotoxic in the absence of serum (41), we did not observe any effect on cell viability when HeLa-CD4-CCR5 were treated with HD5 or HD6 in the absence of serum (data not shown).

FIGURE 2. HD5 and HD6 did not affect cell proliferation or HIV infection after viral entry. A, PHA-activated CD4⁺ T cells were incubated with HD5 or HD6 at various concentrations for 24 h. Cell viability was measured by Promega CellTiter 96 aqueous MTS assay. No difference was observed in cells in the absence or presence of HD5 or HD6 (p > 0.05). (B and C) To determine the effect of HD5 and HD6 on HIV infection after viral entry, HeLa-CD4-CCR5 cells or PHA-activated primary CD4⁺ T cells were infected with pseudotyped HIVᵱᵥᵱ reporter virus for 2 h. Cells were washed and treated with HD5 or HD6 at various concentrations for 48 h before measuring luciferase activity. No difference was found between the control (without treatment) and defensin-treated samples (p > 0.05). Data are means ± SD of triplicate samples and represent three independent experiments. R.L.U., reflective light units.

FIGURE 3. HD5 and HD6 promoted infection of HIV primary isolates in activated primary CD4⁺ T cells. HIV-1 primary isolates using R5 or X4R5 coreceptors (A–C) and a laboratory-adapted strain HIV₋₁₁₁₃ (D) were treated with HD5 and HD6 at various concentrations at 37°C for 1 h before addition to PHA-activated primary CD4⁺ T cells for 2 h. Cells were washed and incubated in RPMI 1640 containing 10% FBS and IL-2 in the absence of defensins. HIV-1 production was measured and the levels of HIV-1 p24 at days 0 (baseline), 3, 5, 7, and 10 after viral infection. For HIV₋₁₁₁₃, the p24 level at day 10 is shown. The names and tropisms of virus isolates are indicated and viral genotypes are shown in parentheses. Difference between nontreated control and primary isolates with treatment of defensins at day 10 after viral infection is significant; p < 0.05. Data are means ± SD of triplicate samples and represent two independent experiments.
To further determine whether HD5 and HD6 exerted an effect on HIV-1 infection by acting on the target cells, PHA-activated primary CD4+ T cells, HeLa-CD4-CCR5 cells, or U87-CD4-CCR5 cells were exposed to HIV-1vsv luciferase reporter virus for 2 h, washed, and then treated with HD5 or HD6 at varying concentrations for 48 h before measurement of luciferase activity. We did not observe any post-entry effect of HD5 and HD6 on active primary CD4+ T cells, HeLa-CD4-CCR5 cells, or U87-CD4-CCR5 cells (data not shown). Similar results were obtained when HIV-1R8-2, pseudotyped virus was used (data not shown). Because HD5 and HD6 had no effect on HIV infection after viral entry (Fig. 2, B and C), we concluded that these peptides enhance HIV infection at the level of viral entry.

**HD5 and HD6 enhance infection of HIV primary isolates**

To determine the potential relevance of this enhancement, we assessed whether HD5 and HD6 also enhanced infection with HIV primary isolates. HIV R5 and X4R5 primary isolates produced in PBMCs were incubated with HD5 and HD6 at various concentrations at 37°C for 1 h before exposure to activated primary CD4+ T cells for an additional 2 h. Cells were then washed with PBS and incubated in medium with 10% FBS and IL-2. HIV production in the medium was monitored by HIV p24 assay. A laboratory-adapted X4 strain HIVm was also included for comparison. When present only during the initial infection, HD5 and HD6 enhanced infection of primary isolates in a multiple-round infection assay (Fig. 3). HD5 and HD6 at concentrations >10 μg/ml promoted HIV-1 infection by 3- to 53-fold depending on the virus strain in activated primary CD4+ T cells.

We further examined whether HD5 and HD6 enhanced viral entry of various subtypes of HIV-1 primary isolates using TZM-bl indicator cells. TZM-bl cells expressing CD4, CXCR4, and CCR5 coreceptors also contain an HIV LTR-driven luciferase reporter gene that is activated by HIV Tat protein during productive HIV infection. Replication-competent X4, R5, or X4R5 primary isolates were incubated with HD5 or HD6 at 37°C for 1 h before exposure to TZM-bl indicator cells. After incubation at 37°C for 2 h, cells were washed and incubated for 48 h before measurement of luciferase activity. HD5 and HD6 promoted infection of different subtypes of X4, R5, and dual tropic X4R5 HIV-1 primary isolates (Table I). The enhancing effect of HD5 was more pronounced on HIV R5 viruses as compared with X4 viruses, an important observation in light of the fact that R5 viruses are almost exclusively transmitted (47).

**Disulfide bonding of defensins is required to enhance HIV infection**

To determine whether the structure of HD5 or HD6 is required for HIV enhancement, we compared the effect on HIV entry of HD5 or HD6 with that of linear analogues with mutations in the Cys residues, have been shown to be unstructured in aqueous solution by circular dichroism spectroscopy (Ref. 50 and data not shown for HD5). [Abu]HD5 and [Abu]HD6, in which Abu replaces the -SH group (48, 49), and is used to block the disulfide bridges in HD5 or HD6. [Abu]HD5 and [Abu]HD6, in which Abu replaces all six Cys residues, have been shown to be unstructured in aqueous solution by circular dichroism spectroscopy (Ref. 50 and data not shown for HD5). HD5 R9H, a known single nucleotide polymorphism, and HD5 R13H, an analog with Arg replaced by His, both contain intact disulfide bonds and both exhibited HIV-enhancing effects (Fig. 4A, p < 0.001 between untreated control and mutants).
However, the HIV enhancing effects of HD5 R9H and HD5 R13H were less than that of wild type ($p = 0.025$ for HD5 R9H and $p = 0.005$ for HD5 R13H), suggesting that host polymorphisms may modulate defensin-mediated enhanced HIV infectivity. Importantly, in contrast to wild-type HD5 and HD6, [Abu]HD5 and [Abu]HD6 no longer enhanced HIV replication (Fig. 4, A and B). Because wild-type defensins and their linear analogues have the same charge, this result suggests that the HIV-enhancing effect requires a specific structural conformation and is not due to simple charge-charge interactions alone.

**Viral enhancement by HD5 and HD6 is CD4 and coreceptor independent**

To determine whether defensin-mediated viral enhancement was dependent on CD4 and coreceptors, HIV reporter viruses were pseudotyped with VSV or murine leukemia virus envelopes that do not use CD4 and CXCR4 or CCR5 coreceptors for viral entry. HIV luciferase reporter viruses pseudotyped with HIV-1HxB2(X4), HIV-1JR-FL(R5), and a primary isolate HIV-1RB23-1 (R5) envelope (51) were also included in this study. The direct effect of HD5 and HD6 (10$^{6}$ g/ml) on the virion was determined using a single-cycle infection assay. Similar to the finding in Table I, HD5 and HD6 enhanced infection of both R5 and X4 HIV strains and the effect

![Figure 5](image)

**Figure 5.** HD5 expresses in vaginal epithelial cells as precursor molecules that enhance HIV infection. A, Whole cell extracts from vaginal epithelial cells (lane 2) were prepared and analyzed by immunoblotting using polyclonal anti-HD5 Ab. Synthetic HD5 peptide (50 ng) was included in lane 1. B, Pseudotyped HIVJR-FL luciferase reporter virus was incubated with recombinant pro-HD5 proteins at different concentrations at 37°C for 1 h before addition to HeLa-CD4-CCR5 cells in the presence of 10% FBS. After 2 h of incubation, cells were washed and cultured in medium with 10% FBS for 48 h before measurement of luciferase activity. Difference between HIV-infected, untreated control, and samples with treatment of pro-HD5 at 10 or 50 μg/ml is significant; *, $p < 0.05$. Data are means ± SD of triplicate samples and represent two independent experiments. R.L.U., reflective light units.

![Figure 6](image)

**Figure 6.** GC infection induces HD5 and HD6 gene expression and enhances HIV infection. A, Immortalized vaginal, endocervical, and ectocervical epithelial cells were infected with *N. gonorrhoeae* (ATCC no. 43069) at a MOI of 10 and cultured at 37°C. Total RNA was prepared at various time points for RT-PCR analysis. Diluted small intestine cDNA (C, as control; Clontech Laboratories) was included as a positive control for the size of PCR products. The identity of PCR products was confirmed by sequencing. B, Conditioned media from vaginal epithelial cells without (-) or with GC exposure (+) were concentrated and expression of HD5 was analyzed by immunoblotting using anti-HD5 Abs. C, Vaginal epithelial cells were exposed to *N. gonorrhoeae* at a MOI of 10 and cultured at 37°C for 48 h. Conditioned medium from cells without or with exposure to GC were incubated with pseudotyped HIVJR-FL luciferase reporter virus at 37°C for 1 h before addition to HeLa-CD4-CCR5 cells in the presence of 10% FBS. Difference between conditioned medium from cells without GC exposure and that from cells with GC exposure is significant; *, $p < 0.05$. Data are means ± SD of triplicate samples and represent two independent experiments. D, To determine the effect of conditioned medium from GC-exposed cells on HIV infection without preincubation with virus, pseudotyped HIVJR-FL luciferase reporter virus mixed with conditioned medium was added to HeLa-CD4-CCR5 cells in the presence of 10% FBS at 37°C for 2 h. Cells were then washed and cultured for 48 h before measurement of luciferase activity. Difference between conditioned medium from cells without GC exposure and that from cells with GC exposure is not significant; $p > 0.05$. R.L.U., reflective light units.
was more striking on R5 virus compared with X4 virus. HD5 and HD6 promoted HIV infection of pseudotyped virus with VSV and murine leukemia virus envelopes that do not use CD4 and coreceptors for viral entry (Table II), indicating that the viral enhancement was not dependent on CD4 and coreceptors.

**HD5 is expressed in vaginal epithelial cells as precursor molecules that enhance HIV infection**

Expression of HD5 proteins has been demonstrated in tissues from normal vagina, ectocervix, and endocervix (52). HD5 is produced as pre-pro-peptides and the pro-peptide is released and processed extracellularly in the small intestine (53). HD5 is present as precursor molecules in cervicovaginal lavage from normal women (52) and in the male urethra during STIs (29). Similar to previous reports, HD5 precursor molecules were detected in vaginal epithelial cells by immunoblotting using Ab against HD5 (Fig. 5A). We accessed the effect of recombinant pro-HD5 (aa 22–94) on HIV infection using a single-cycle infection and observed that pro-HD5 protein at 50 μg/ml promoted HIV infection of HeLa-CD4-CCR5 cells by 11-fold (p < 0.05).

**N. gonorrhoeae infection induces gene expression of HD5 and HD6 and enhances HIV infection**

The expression of HD5 has been shown in reproductive tract tissues (25, 52). In addition, elevated levels of HD5 are found in the urethral discharge during *N. gonorrhoeae* and *C. trachomatis* infection (29). Thus, we hypothesized that bacterial STIs could induce HD5 and HD6 expression in genital epithelial cells that, in turn, could enhance HIV infectivity. We exposed immortalized human vaginal, endocervical, and ectocervical epithelial cells to *N. gonorrhoeae* (ATCC no. 43069) and expression of HD5 and HD6 was measured by RT-PCR analysis at various time points after bacterial exposure. As a control, diluted cDNA from small intestine tissue, where HD5 and HD6 are highly abundant, was included in the PCR analysis. We observed that expression of HD5 and HD6 was induced in cervicovaginal epithelial cells in response to GC infection (Fig. 6A).

We then confirmed the presence of HD5 in conditioned medium from GC-exposed cervicovaginal epithelial cells by immunoblotting using polyclonal Abs against HD5 that react with both pro-HD5 and fully processed HD5 (41, 53). In agreement with a previous report demonstrating HD5 precursor molecules in cervicovaginal lavage from normal women (52), HD5 was produced and released as precursor molecules in vaginal and ectocervical epithelial cells (Fig. 6B and data not shown for ectocervical epithelial cells). Similar to HD5 precursors from intestine (53), HD5 precursors in cervicovaginal epithelial cells were sensitive to trypsin and processed into mature peptides in vitro (data not shown). In addition, the level of HD5 was increased in conditioned medium from GC-exposed epithelial cells compared with non-treated control samples (Fig. 6B).

To determine whether conditioned medium from GC-infected vaginal epithelial cells containing elevated level of HD5 (and possibly HD6) could enhance HIV infection, vaginal epithelial cells were exposed to GC for 48 h and conditioned medium was collected for the HIV entry assay. HIVJR-FL-pseudotyped reporter virus was preincubated with conditioned medium at 37°C for 1 h before the infection of HeLa-CD4-CCR5 cells (Fig. 6C). As a control, virus and conditioned medium were added directly to cells without preincubation (Fig. 6D). Conditioned medium from GC-exposed cells had little effect on the target cells during the 2-h incubation time (Fig. 6D). However, HIV infectivity was enhanced when viruses were preincubated with conditioned medium from GC-infected cells before exposure to the target cells (Fig. 6C).

**siRNAs targeting HD5 or HD6 diminished GC-mediated enhanced HIV infectivity**

To obtain direct evidence for an involvement of HD5 or HD6 in GC-mediated enhanced HIV infectivity, we transfected siRNAs targeting HD5 or HD6 and negative control siRNAs into vaginal epithelial cells. Transfected cells were incubated overnight and exposed to GC for 48 h before collection of conditioned medium and total RNAs for HIV infection assay and RT-PCR analysis, respectively. While transfection of negative control siRNAs did not have a significant effect on enhanced HIV infectivity by GC, introduction of siRNAs targeting HD5 or HD6 significantly diminished GC-mediated enhanced HIV infectivity (Fig. 7A). In addition, we did not observe induction of HD5 or HD6 by GC in cells transfected with siRNAs for HD5 or HD6, whereas GC infection induced HD5 and HD6 gene expression in cells transfected with negative control siRNAs (Fig. 7B). Taken together, these results indicated that HD5 and HD6 play a role in GC-mediated enhanced HIV infection.
Discussion

Previous studies have shown that human defensins inhibit infection of various viruses, including HIV (reviewed in Ref. 31). In this study, we provide evidence that HD5 and HD6 can promote HIV infection in various experimental settings. HD5 and HD6 enhanced HIV infection at the step of viral entry, and these peptides promoted R5 virus, the predominant strain transmitted, to a greater extent than X4 virus. In light of the report demonstrating elevation of HD5 proteins by 10- to 30-fold in urethral fluid from men with STIs (29), we hypothesized that STIs may induce expression of HD5 and HD6 and, in turn, could enhance vaginal transmission of HIV. Indeed, we found that GC infection of cervicovaginal epithelial cells induced HD5 and HD6 expression (Fig. 6A). Importantly, conditioned medium from GC-exposed epithelial cells contained HD5 and promoted HIV infection (Fig. 6A). Furthermore, introduction of siRNAs targeting HD5 or HD6 blocked GC-mediated enhanced HIV infectivity. Because HD5 is normally present at a concentration of 1 µg/ml in vaginal fluid (52), an increase of HD5 and HD6 levels to 10 µg/ml, which is sufficient to enhance HIV infection in vitro, could promote HIV transmission in women with STIs.

Our findings are in contrast to those reported by Tanabe et al. (54), who demonstrated that recombinant HD5 had no effect on HIV replication in the transformed T cell line MT-2. This discrepancy is most likely due to the choice of target cells, as has been demonstrated with HNP1-mediated inhibition of HIV (34, 55). Importantly, we observed the enhancement of HIV in the primary target cells, CD4+ T cells. Additionally, we incubated defensins and virus in PBS rather than water, which may also account for the discrepancy, as the effect of HBDs on the HIV virion only occurs under a low salt conditions (10 mM phosphate buffer) (32). Interestingly, Tanabe et al. did find that cryptdin3, a mouse enteric defensin ortholog, enhanced HIV infection (54). The effects of defensins on virus replication, particularly HIV, are quite complex and defensin specific.

Our results suggest that interactions with HIV glycoproteins may play a role in defensin-mediated enhancement of HIV infectivity. The maximal HIV-enhancing effect of HD5 and HD6 was achieved when HIV was preincubated with defensins. In addition, the promoting effect of HD5 and HD6 was more pronounced on R5 virus compared with X4 virus. It is possible that the relatively modest enhancing effect of defensins on X4 viruses was due to the high positive charge of X4 gp120 proteins, which may inhibit the interactions with the positively charged defensins. As HD5 and HD6 appeared to enhance HIV entry, we are currently dissecting specific steps of the early HIV life cycle, including attachment and fusion mediated by these peptides, as well as determining the specific region(s) of HIV envelopes that interact with HD5 and HD6 and the influence of HIV gp120 charge to these interactions and to the HIV-enhancing effect.

Polycationic polymers, such as Polybrene, have been used to enhance the infection of HIV and other retroviruses (56–63). It is possible that defensins act like polycationic polymers to promote HIV infection as they are positively charged. The viral enhancement of Polybrene is thought to be mediated through increased viral adsorption as a consequence of decreased repulsive forces between virions and cells, both of which contain negatively charged lipid membranes. Davis et al. have shown that enhancement of retrovirus transduction by polybrene is receptor and envelope independent (59). In addition to a neutralizing membrane charge, positive charge polymers >15 kDa in size can promote infection through virus aggregation (58). We demonstrated that HD5 and HD6 increased HIV infection in a glycoprotein-dependent and HIV receptor-independent manner. Furthermore, HD5 and HD6 linear analogues with the same charge as their structured counterparts failed to promote HIV infection (Fig. 4). These results suggest that neutralizing negative charges on viral envelopes or target cell membranes cannot fully account for defensin-mediated HIV enhancement, although charge may be important in the context of proper conformation. It remains to be determined whether proper formation of hydrophobic domains facilitates membrane fusion upon viral entry.

HD5 and HD6 have been shown to exhibit antiviral activity against other sexually transmitted viruses such as human papillomavirus (a nonenveloped virus) and HSV-2 (64, 65), although their antiviral mechanisms are distinct. HD5 does not affect binding and entry of human papillomavirus but prevents virion release from the endosome (64). HD5 and HD6 appear to block HSV-2 infection via different mechanisms (65). Although HD6 inhibits HSV-2 attachment and penetration, HD5 blocks later stages of the HSV-2 life cycle. HD6 binds to heparan sulfate, required for HSV-2 attachment on the target cells, whereas HD5 binds to HSV-2 gb, which is essential for viral penetration but does not bind to heparan sulfate. These interactions are quite specific and distinct for each defensin.

We observed differential HIV enhancing effects of HD5 and HD6 between HeLa-CD4-CCR5 and primary CD4+ T cells, implicating factors on the target cell that influence the effect. The levels of glycosaminoglycans and ICAM vary between adherent cells (HeLa cells) and suspension cells (CD4+ T cells) and can modulate HIV attachment (reviewed in Ref. 66). It is possible that the defensin-mediated effect alters HIV envelope interactions with glycosaminoglycans, including heparan sulfate and chondroitin sulfate on the cell surface, as glycosaminoglycans influence HIV attachment in an envelope-dependent and coreceptor-independent manner (56, 66).

In response to an invasion of pathogens, HBDs are known to be induced through TLR2 and TLR4 activation as well as via proinflammatory cytokines such as IL-1 (23, 31, 67). Activation of TLR2 or TLR4 induces HBD2 in immortalized vaginal epithelial cells via the NF-κB pathway (68). Although it has been suggested that TNF-α and LPS can induce HD5 (52), the HD5 gene contains an IFN response element in the promoter region (29) and can be induced in response to IFN-γ in HeLa cells (E. Porter, unpublished data). With respect to induction of HD5 and HD6 by GC infection, it remains to be determined whether TLR activation via bacterial LOS or porins directly modulates expression of HD5 and HD6 or via the production of cytokines such as IFNs and TNF-α.

Gonococcal pili and colony Opa proteins play a role in GC adherence to and invasion of epithelial cells (69–71), although GC can invade epithelial cells via a LOS-dependent and Opa-independent manner (72). Fichorova et al. have demonstrated that both piliated and nonpiliated gonococci can induce proinflammatory host cytokine responses despite their different abilities to invade epithelial cells (19). It remains to be determined whether the presence of pili or Opa affects GC-mediated induction of defensin gene expression and enhanced HIV infectivity as we did not characterize the expression of pili and Opa by the gonococcal strain used in these studies.

HD5 is primarily secreted as precursor molecules in the lumen of the normal small intestine and female vaginal tract and the inflamed male urethra (29, 53, 73–75). In contrast to HNPs that are processed intracellularly in neutrophils (23), HD5 is cleaved upon secretion by trypsin in the small intestine and neutrophil protease in inflamed penile urethra (29, 53). We observed that cervicovaginal epithelial cells produced HD5 precursor molecules in response
to GC infection and that pro-HD5 enhanced HIV infection at similar molar levels as HD5. The concentration of HD5 precursor molecules in the conditioned medium from GC-exposed vaginal epithelial cells that enhanced HIV infection was ~1 µg/ml by Western blot analysis using synthetic HD5 as a standard, ~10-fold less than that required to enhance HIV infection in vitro. However, considering the much larger medium volume covering cultured epithelial cells compared with the much smaller volume of mucus covering vaginocervical cells in vivo, it is likely that HD5 concentrations affecting HIV infectivity are reached in vivo. Furthermore, native HD5 appears to be in part glycosylated (53), affecting its antibacterial activity, and it needs to be determined whether vaginocervical cells release glycosylated HD5 with stronger HIV-inducing activity. Venkataraman et al. demonstrated that the anti-HIV activity of cation-depleted vaginal fluid can be fully restored by adding back the cationic polypeptide fraction, but the activity is only restored partially by using a mixture of different recombinant cationic polypeptides (76). It is also likely that native HD5 proteins at a lower concentration could promote HIV infectivity by interacting with other proteins in conditioned medium from GC-exposed epithelial cells. In support of these possibilities, introduction of siRNAs targeting HD5 and HD6 blocked the HIV-enhancing effect of the conditioned medium from GC-exposed cells, demonstrating that HD5 and HD6 play a direct role in GC-mediated enhanced HIV infectivity.

Induction of HNPs and HD5 has been reported in the male urethra during C. trachomatis and N. gonorrhoeae infection (29). Although neutrophil infiltration accompanied by elevation of HNPs is the major vaginal immune response to most STIs (27, 77, 78), induction of other defensins such as HBDS, HD5, and HD6 in women with C. trachomatis and N. gonorrhoeae infection has not been reported. N. gonorrhoeae is resistant to HNPs but not to HD5 and its precursor (29, 79–81). Pro-HD5, processed by neutrophil proteases in the urogenital mucosa in men with STIs, also exerts antibacterial activity against N. gonorrhoeae (29). It remains to be determined whether HD5 and HD6 are elevated in women with C. trachomatis and N. gonorrhoeae infection and whether elevation of HD5 and HD6 by GC results in controlling bacterial growth but at the same time enhancing HIV infection in vivo. Furthermore, as GC can induce anti-HIV factors such as HBDS, RANTES, MIP-1α, and MIP-1β, which may moderate the HIV enhancing effect of HD5, the interaction between these anti-HIV factors and HD5/HD6 and their net effect on HIV infection may be complex and dynamic. Thus, further studies are warranted to determine how different defensins inhibit or enhance HIV entry as well as affect the overall outcome of HIV infection in the presence of various peptides at physiological concentrations.

In summary, we report a novel mechanism by which STIs, specifically GC, could enhance HIV transmission through up-regulation of the defensins HD5 and HD6. In addition to promoting HIV entry, HD5 can induce cytokines such as IL-8 (50) that may increase HIV transmission within the cervicovaginal mucosa (82). Understanding the mechanism of HD5- and HD6-mediated HIV enhancement and the complex contribution of these host factors to transmission is critically important for the development of new strategies for HIV prevention, particularly those that target or alter the vaginal mucosa.

Acknowledgments

We thank Flora Samaroo for providing Neisseria gonorrhoeae, Bernadette Benito for technical assistance, and Viviana Simon and members of the Klotman laboratories for helpful discussions.

Disclosures

The authors have no financial conflict of interest.

References


Downloaded from http://www.jimmunol.org/ by guest on April 15, 2017


